IMMUNOGENICITY AND EFFICACY OF VACCINES AGAINST BOVINE BRUCELLOSIS
Brucellosis, vaccination, RB51, S19.
Brucellosis is a chronic disease that affects several animal species, including humans, cattle and buffalo, and has worldwide distribution. Brucella abortus is the main species causing bovine brucellosis and leads to several economic losses, mainly due to abortions, stillbirth and infertility. In humans, brucellosis is a chronic and debilitating illness and is transmitted through ingestion of unpasteurized milk and dairy products or through contact with fetuses and abortion products from infected animals. Vaccination of young bovine females (between 3 and 8 months) with S19 or RB51 live strains is one of the major measures for brucellosis control worldwide, aiming both human and animal health. However, although the two vaccine strains have been widely used, they confer only 60-70% of protection against infection and abortion, value still far from being considered as ideal. In addition, many aspects of bovine vaccination with S19 and RB51 remain still unclear as whether there is or not an ideal age at vaccination for improving immune response; the effectiveness (field efficacy) of these strains. At that, the objective of this thesis is to evaluate immunogenicity and efficacy of vaccines against bovine brucellosis